Engineered EVs (EEVs) are an emerging form of precision medicine with immense promise and application in key areas such as neurology, cardiology and oncology. EEVs can be directed to certain cell types and carry powerful cargos, such as RNA, enzymes and/or small molecules. Because of their cellular provenance, EEVs avoid critical limitations of other delivery vehicles such as liposomes and other synthetic nanoparticles. Exopharm has a number of EEV projects under development including Fortrexo for combating viral infections and Cognevo for the delivery of drugs to the central nervous system.
Exopharm’s EVPS technology was in-licensed in 2020 from Santa Clara University USA and enables the addition of custom surface proteins to exosomes for targeting to specific tissues. Our LOAD technology, in-licensed from the State University of New York at Buffalo USA, enables us to load EVs with specialised therapeutic cargo.